Techdata Service Company
Techdata Service Company is recorded as a service provider in 14 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 14 of 14 trials · Latest update first
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 1)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants with Type 2 Diabetes Mellitus who have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-2)
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT+KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 2)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared with Placebo in Adult Participants with Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- A substantial global amendment on 31 October 2023 added laboratory monitoring during dose escalation in response to regulatory feedback.
These findings describe the trial, not the service provider’s performance or responsibility.
I5T-MC-AACO: Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
J1I-MC-GZBP: A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
J2A-MC-GZGP A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of SIR9900 in Patients with VEXAS Syndrome (SIVEX)
Sponsor Sironax USA Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
J1I-MC-GZBM: A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants with Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3)
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
J1I-MC-GZBN:A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants who have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
J2J-OX-JZLC: EMBER-3: A Phase 3, Randomized, Open-label Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with Estrogen receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with endocrine Therapy
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
J1I-MC-GZBJ: A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1); J1I-MC-GOA1: Indication-Specific Appendix (ISA2) for participants with knee osteoarthritis (OA)
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
(Summit) A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with NonAdvanced Systemic Mastocytosis
Sponsor Cogent Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
I5T-MC-AACI: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Techdata Service Company?
The 2026-10-09 snapshot links Techdata Service Company to 14 distinct CTIS trials. Recorded services include Statistical analysis, Data management, Biostatistics and Statistical Programming, DMC Support, Biostatistics and Statistical Programming,DMC Support, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Techdata Service Company?
The most frequently recorded therapeutic areas are Endocrinology, Metabolic Disorders, Neurology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Techdata Service Company conducted?
The linked trials record locations in 18 countries, including Spain, Poland, Germany, Greece, Italy. These are trial locations, not confirmed office locations or countries where Techdata Service Company delivered services.
What can this page tell me about Techdata Service Company's trial experience?
Browse 14 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Techdata Service Company. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Techdata Service Company LLC